What is the projected market valuation for Primary Sclerosing Cholangitis in 2035?

The projected market valuation for Primary Sclerosing Cholangitis in 2035 is 0.2711 USD Billion. Read More

What was the overall market valuation for Primary Sclerosing Cholangitis in 2024?

The overall market valuation for Primary Sclerosing Cholangitis in 2024 was 0.16 USD Billion. Read More

What is the expected CAGR for the Primary Sclerosing Cholangitis Market from 2025 to 2035?

The expected CAGR for the Primary Sclerosing Cholangitis Market during the forecast period 2025 - 2035 is 4.91%. Read More

Which companies are key players in the Primary Sclerosing Cholangitis Market?

Key players in the Primary Sclerosing Cholangitis Market include AbbVie, Gilead Sciences, Bristol-Myers Squibb, Novartis, Merck & Co., Amgen, Roche, Eli Lilly and Company, and Pfizer. Read More

How do diagnostic procedures contribute to the Primary Sclerosing Cholangitis Market?

Diagnostic procedures such as Magnetic Resonance Cholangiopancreatography (MRCP), Liver Biopsy, and Blood Tests contribute with valuations between 0.04 and 0.1211 USD Billion. Read More

What is the market segmentation based on disease severity for Primary Sclerosing Cholangitis?

Market segmentation based on disease severity includes Early Stage, Intermediate Stage, and Advanced Stage, with valuations from 0.05 to 0.1 USD Billion. Read More

What comorbidities are associated with Primary Sclerosing Cholangitis?

Comorbidities associated with Primary Sclerosing Cholangitis include Ulcerative Colitis, Crohn's Disease, and Autoimmune Hepatitis, with valuations between 0.04 and 0.1 USD Billion. Read More

What pipeline therapies are being developed for Primary Sclerosing Cholangitis?

Pipeline therapies for Primary Sclerosing Cholangitis include FXR Agonists, IL-12/23 Inhibitors, and JAK Inhibitors, with valuations ranging from 0.03 to 0.085 USD Billion. Read More

How does the market for Primary Sclerosing Cholangitis compare to previous years?

The market for Primary Sclerosing Cholangitis is expected to grow from 0.16 USD Billion in 2024 to 0.2711 USD Billion by 2035, indicating a positive trend. Read More

Primary Sclerosing Cholangitis Market

Q: What are the main treatment segments in the Primary Sclerosing Cholangitis Market?

The main treatment segments include Medications, Surgery, and Endoscopic Retrograde Cholangiopancreatography (ERCP), with valuations ranging from 0.04 to 0.14 USD Billion. Read More

ID: MRFR/HC/25425-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Primary Sclerosing Cholangitis Market Research Report By Treatment (Medications, Surgery, Endoscopic Retrograde Cholangiopancreatography (ERCP)), By Diagnostic Procedures (Magnetic Resonance Cholangiopancreatography (MRCP), Liver Biopsy, Blood Tests), By Disease Severity (Early Stage, Intermediate Stage, Advanced Stage), By Comorbidities (Ulcerative Colitis, Crohn's Disease, Autoimmune Hepatitis), By Pipeline Therapies (FXR Agonists, IL-12/23 Inhibitors, JAK Inhibitors) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Primary Sclerosing Cholangitis Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Treatment (USD Billion) | |
  1. 4.1.1 Medications | |
  2. 4.1.2 Surgery | |
  3. 4.1.3 Endoscopic Retrograde Cholangiopancreatography (ERCP) |
2. 4.2 Healthcare, BY Diagnostic Procedures (USD Billion) | |
  1. 4.2.1 Magnetic Resonance Cholangiopancreatography (MRCP) | |
  2. 4.2.2 Liver Biopsy | |
  3. 4.2.3 Blood Tests |
3. 4.3 Healthcare, BY Disease Severity (USD Billion) | |
  1. 4.3.1 Early Stage | |
  2. 4.3.2 Intermediate Stage | |
  3. 4.3.3 Advanced Stage |
4. 4.4 Healthcare, BY Comorbidities (USD Billion) | |
  1. 4.4.1 Ulcerative Colitis | |
  2. 4.4.2 Crohn's Disease | |
  3. 4.4.3 Autoimmune Hepatitis |
5. 4.5 Healthcare, BY Pipeline Therapies (USD Billion) | |
  1. 4.5.1 FXR Agonists | |
  2. 4.5.2 IL-12/23 Inhibitors | |
  3. 4.5.3 JAK Inhibitors |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Gilead Sciences (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Bristol-Myers Squibb (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Novartis (CH) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Merck & Co. (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Amgen (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Roche (CH) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Eli Lilly and Company (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Pfizer (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TREATMENT |
7. 6.4 US MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
8. 6.5 US MARKET ANALYSIS BY DISEASE SEVERITY |
9. 6.6 US MARKET ANALYSIS BY COMORBIDITIES |
10. 6.7 US MARKET ANALYSIS BY PIPELINE THERAPIES |
11. 6.8 CANADA MARKET ANALYSIS BY TREATMENT |
12. 6.9 CANADA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
13. 6.10 CANADA MARKET ANALYSIS BY DISEASE SEVERITY |
14. 6.11 CANADA MARKET ANALYSIS BY COMORBIDITIES |
15. 6.12 CANADA MARKET ANALYSIS BY PIPELINE THERAPIES |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT |
18. 6.15 GERMANY MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
19. 6.16 GERMANY MARKET ANALYSIS BY DISEASE SEVERITY |
20. 6.17 GERMANY MARKET ANALYSIS BY COMORBIDITIES |
21. 6.18 GERMANY MARKET ANALYSIS BY PIPELINE THERAPIES |
22. 6.19 UK MARKET ANALYSIS BY TREATMENT |
23. 6.20 UK MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
24. 6.21 UK MARKET ANALYSIS BY DISEASE SEVERITY |
25. 6.22 UK MARKET ANALYSIS BY COMORBIDITIES |
26. 6.23 UK MARKET ANALYSIS BY PIPELINE THERAPIES |
27. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT |
28. 6.25 FRANCE MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
29. 6.26 FRANCE MARKET ANALYSIS BY DISEASE SEVERITY |
30. 6.27 FRANCE MARKET ANALYSIS BY COMORBIDITIES |
31. 6.28 FRANCE MARKET ANALYSIS BY PIPELINE THERAPIES |
32. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT |
33. 6.30 RUSSIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
34. 6.31 RUSSIA MARKET ANALYSIS BY DISEASE SEVERITY |
35. 6.32 RUSSIA MARKET ANALYSIS BY COMORBIDITIES |
36. 6.33 RUSSIA MARKET ANALYSIS BY PIPELINE THERAPIES |
37. 6.34 ITALY MARKET ANALYSIS BY TREATMENT |
38. 6.35 ITALY MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
39. 6.36 ITALY MARKET ANALYSIS BY DISEASE SEVERITY |
40. 6.37 ITALY MARKET ANALYSIS BY COMORBIDITIES |
41. 6.38 ITALY MARKET ANALYSIS BY PIPELINE THERAPIES |
42. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT |
43. 6.40 SPAIN MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
44. 6.41 SPAIN MARKET ANALYSIS BY DISEASE SEVERITY |
45. 6.42 SPAIN MARKET ANALYSIS BY COMORBIDITIES |
46. 6.43 SPAIN MARKET ANALYSIS BY PIPELINE THERAPIES |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY DISEASE SEVERITY |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY COMORBIDITIES |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY PIPELINE THERAPIES |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY TREATMENT |
54. 6.51 CHINA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
55. 6.52 CHINA MARKET ANALYSIS BY DISEASE SEVERITY |
56. 6.53 CHINA MARKET ANALYSIS BY COMORBIDITIES |
57. 6.54 CHINA MARKET ANALYSIS BY PIPELINE THERAPIES |
58. 6.55 INDIA MARKET ANALYSIS BY TREATMENT |
59. 6.56 INDIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
60. 6.57 INDIA MARKET ANALYSIS BY DISEASE SEVERITY |
61. 6.58 INDIA MARKET ANALYSIS BY COMORBIDITIES |
62. 6.59 INDIA MARKET ANALYSIS BY PIPELINE THERAPIES |
63. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT |
64. 6.61 JAPAN MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
65. 6.62 JAPAN MARKET ANALYSIS BY DISEASE SEVERITY |
66. 6.63 JAPAN MARKET ANALYSIS BY COMORBIDITIES |
67. 6.64 JAPAN MARKET ANALYSIS BY PIPELINE THERAPIES |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY DISEASE SEVERITY |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY COMORBIDITIES |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY PIPELINE THERAPIES |
73. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT |
74. 6.71 MALAYSIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
75. 6.72 MALAYSIA MARKET ANALYSIS BY DISEASE SEVERITY |
76. 6.73 MALAYSIA MARKET ANALYSIS BY COMORBIDITIES |
77. 6.74 MALAYSIA MARKET ANALYSIS BY PIPELINE THERAPIES |
78. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT |
79. 6.76 THAILAND MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
80. 6.77 THAILAND MARKET ANALYSIS BY DISEASE SEVERITY |
81. 6.78 THAILAND MARKET ANALYSIS BY COMORBIDITIES |
82. 6.79 THAILAND MARKET ANALYSIS BY PIPELINE THERAPIES |
83. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT |
84. 6.81 INDONESIA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
85. 6.82 INDONESIA MARKET ANALYSIS BY DISEASE SEVERITY |
86. 6.83 INDONESIA MARKET ANALYSIS BY COMORBIDITIES |
87. 6.84 INDONESIA MARKET ANALYSIS BY PIPELINE THERAPIES |
88. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT |
89. 6.86 REST OF APAC MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
90. 6.87 REST OF APAC MARKET ANALYSIS BY DISEASE SEVERITY |
91. 6.88 REST OF APAC MARKET ANALYSIS BY COMORBIDITIES |
92. 6.89 REST OF APAC MARKET ANALYSIS BY PIPELINE THERAPIES |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT |
95. 6.92 BRAZIL MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
96. 6.93 BRAZIL MARKET ANALYSIS BY DISEASE SEVERITY |
97. 6.94 BRAZIL MARKET ANALYSIS BY COMORBIDITIES |
98. 6.95 BRAZIL MARKET ANALYSIS BY PIPELINE THERAPIES |
99. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT |
100. 6.97 MEXICO MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
101. 6.98 MEXICO MARKET ANALYSIS BY DISEASE SEVERITY |
102. 6.99 MEXICO MARKET ANALYSIS BY COMORBIDITIES |
103. 6.100 MEXICO MARKET ANALYSIS BY PIPELINE THERAPIES |
104. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT |
105. 6.102 ARGENTINA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
106. 6.103 ARGENTINA MARKET ANALYSIS BY DISEASE SEVERITY |
107. 6.104 ARGENTINA MARKET ANALYSIS BY COMORBIDITIES |
108. 6.105 ARGENTINA MARKET ANALYSIS BY PIPELINE THERAPIES |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE SEVERITY |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY COMORBIDITIES |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY PIPELINE THERAPIES |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DISEASE SEVERITY |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY COMORBIDITIES |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY PIPELINE THERAPIES |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DISEASE SEVERITY |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY COMORBIDITIES |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY PIPELINE THERAPIES |
125. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT |
126. 6.123 REST OF MEA MARKET ANALYSIS BY DIAGNOSTIC PROCEDURES |
127. 6.124 REST OF MEA MARKET ANALYSIS BY DISEASE SEVERITY |
128. 6.125 REST OF MEA MARKET ANALYSIS BY COMORBIDITIES |
129. 6.126 REST OF MEA MARKET ANALYSIS BY PIPELINE THERAPIES |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY TREATMENT, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY DIAGNOSTIC PROCEDURES, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY DIAGNOSTIC PROCEDURES, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY DISEASE SEVERITY, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY DISEASE SEVERITY, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY COMORBIDITIES, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY COMORBIDITIES, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY PIPELINE THERAPIES, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY PIPELINE THERAPIES, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DIAGNOSTIC PROCEDURES, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY DISEASE SEVERITY, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY COMORBIDITIES, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY PIPELINE THERAPIES, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Treatment (USD Billion, 2025-2035)

Medications
Surgery
Endoscopic Retrograde Cholangiopancreatography (ERCP)

Healthcare By Diagnostic Procedures (USD Billion, 2025-2035)

Magnetic Resonance Cholangiopancreatography (MRCP)
Liver Biopsy
Blood Tests

Healthcare By Disease Severity (USD Billion, 2025-2035)

Early Stage
Intermediate Stage
Advanced Stage

Healthcare By Comorbidities (USD Billion, 2025-2035)

Ulcerative Colitis
Crohn's Disease
Autoimmune Hepatitis

Healthcare By Pipeline Therapies (USD Billion, 2025-2035)

FXR Agonists
IL-12/23 Inhibitors
JAK Inhibitors

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓